2-Phenylpropanoic acid biocatalysts Pharma Grade API is supplied as a white to off-white crystalline powder under model identifiers BC-PPA-01 and BC-PPA-02. The compound (CAS 492-37-5, C₉H₁₀O₂, molar mass 150.17 g/mol) is manufactured by enantioselective hydrolysis of the corresponding racemic ester using an immobilized lipase B from Candida antarctica (EC 3.1.1.3) supported on macroporous polymethacrylate resin. BC-PPA-01 is the non-sterile oral grade intended for tablet, capsule, and granule dosage forms; BC-PPA-02 is the low-endotoxin injectable grade intended for oral solutions and parenteral liquids after aseptic filtration. The route does not use chiral amine resolving agents, thereby excluding residual amine-derived impurities from the isolate. Manufacturing is conducted under ICH Q7 and 21 CFR 210/211 expectations. Release specifications are aligned with Ph. Eur. 2.2.24, USP <197>, USP <621>, USP <467>, USP <232>, USP <233>, USP <61>, USP <62>, ICH Q3C, and ICH Q3D. The polymorphic form is controlled by XRPD according to USP <941>; the reference pattern corresponds to the stable anhydrous form, and the amorphous fraction is maintained below 5% w/w. For oral solid dosage processing, the particle size distribution is specified as D10 ≥5 µm, D50 15–35 µm, and D90 ≤75 µm by laser diffraction according to USP <429>. Direct compression is preferred over aqueous wet granulation because the free carboxylic acid forms low-friability agglomerates in water-based binder systems; if wet granulation is unavoidable, an isopropanol-based binder is specified to limit hydrate formation and polymorphic shift.

How Is Enantiomeric Excess Verified After Enzyme Removal?

Process control requires ester conversion above 99.0% by HPLC area normalization before harvest; residual ester acceptance is ≤0.5% on the dried basis. The reaction is quenched by pH adjustment to 4.0 ± 0.2 with 2 mol/L hydrochloric acid at 20–25 °C, followed by filtration through a 0.45 µm polyethersulfone membrane and purified water washing. Enzyme removal is verified by residual protein quantification using a Bradford assay and by SDS-PAGE with silver staining; the oral grade permits ≤25 ppm protein, while the injectable grade permits ≤10 ppm. Enantiomeric excess is measured by chiral HPLC on a polysaccharide-based column with n-hexane/isopropanol/trifluoroacetic acid mobile phase under USP <621>; the acceptance criterion is ≥99.0% for BC-PPA-01 and ≥99.5% for BC-PPA-02. The chiral amine diastereomeric salt route generally requires two or three recrystallizations to reach 96–98% enantiomeric excess, with residual resolving agent controlled separately. Published kinetic data for CALB-catalyzed hydrolysis of 2-phenylpropanoate esters under production-scale conditions are limited; the master batch record therefore includes a specific activity check against a qualified working standard before each campaign.

In a direct compression matrix containing microcrystalline cellulose, croscarmellose sodium, and anhydrous colloidal silica, BC-PPA-01 is pre-screened through a 500 µm sieve before blending. A 600 L bin blender at 12 rpm for 15 min produces bulk density values of 0.48–0.55 g/mL and tapped density values of 0.60–0.68 g/mL; the compressibility index is 18–20, which is compatible with rotary tablet press operation at 60 rpm. After lubrication with 0.5% w/w magnesium stearate for 3 min, the mixture is compressed at 8–12 kN on a 12-station rotary press to tablet hardness 60–80 N, with friability below 0.8% after 100 rotations. For capsule filling, a dosator-type machine operating at 30,000 capsules/h maintains fill weight variability within ±3% when hopper relative humidity is below 40%. The oral powder is incompatible with strong bases such as sodium carbonate or meglumine in wet granulation, because in situ salt formation accelerates dissolution but reduces chemical stability at elevated temperature and may cause browning during drying above 50 °C.

Granule Growth and Fragmentation in High-Shear Wet Granulation with Isopropanol Binder

When a granulated intermediate is required, a 25 L high-shear granulator with variable impeller speed should be operated at impeller 300 rpm and chopper 1500 rpm, using an isopropanol/purified water mixture (85:15 v/v) at liquid-to-solid ratio 0.08–0.12 mL/g. Endpoint is reached at granule median diameter 150–250 µm by sieve analysis; wet massing beyond 6 min increases the fine fraction below 75 µm by 8–12% due to breakage of over-wetted agglomerates. Drying in a fluid-bed dryer at inlet air temperature 40–45 °C for 20–30 min reduces moisture content to ≤0.5% w/w; product temperature is maintained below 45 °C to avoid amorphous content above 5%. Granules compressed into tablets using 0.5% w/w magnesium stearate exhibit tensile strength 1.2–1.8 MPa, with disintegration time 3–6 min in purified water at 37 °C according to USP <701>.

Specification Limits for Residual Solvents, Elemental Impurities, and Microbial Attributes

The release matrix separates oral and injectable grades only where route-specific risk changes. Both grades are tested for residual solvents by headspace GC according to USP <467>; ethanol and isopropanol are limited to ≤5000 ppm each, methanol to ≤3000 ppm, and dichloromethane to ≤600 ppm, consistent with ICH Q3C Class 2 and Class 3 options. Elemental impurities are controlled under ICH Q3D Option 1 in the oral grade and Option 2A in the injectable grade; the injectable grade includes a quarterly plasma-atomic emission spectroscopy screen for Pd, Pt, Rh, Ru, Ir, Os, and Mo at a reporting threshold of 1 ppm. Microbial enumeration is performed by membrane filtration according to USP <61> and USP <62>. The injectable grade also requires endotoxin testing by kinetic chromogenic LAL per USP <85> and particulate matter after reconstitution according to USP <788>.

BC-PPA-02 is released as a low-bioburden API, not as a terminally sterilized drug product. For a 10 mg/mL parenteral solution, dissolution is carried out in a buffer of sodium phosphate 50 mmol/L and sodium chloride 9.0 g/L, adjusted to pH 7.4 ± 0.1. The solution is passed through a 0.22 µm polyvinylidene fluoride filter at transmembrane pressure ≤1.0 bar; filter extractables are controlled per USP <665> and USP <1665>. The filtered solution remains clear at 2–8 °C for 24 h. Beyond this hold time, subvisible particle counts above 10 µm can exceed the light obscuration limit of USP <788> for small-volume parenterals. Autoclaving at 121 °C for 15 min is not recommended for the unbuffered acid in the presence of hydroxyl-containing excipients because thermal esterification can shift assay by up to 1.2% and increase the ester impurity above the identification threshold.

When Terminal Sterilization Is Replaced by Aseptic Filtration

Process design for injectable manufacture uses aseptic filtration rather than moist heat sterilization. The filtration train consists of a 0.45 µm prefilter and a 0.22 µm sterilizing-grade filter; both are integrity tested by bubble point or diffusion flow before and after use according to ISO 29463-2 or manufacturer method. Filling is conducted in an ISO 14644-1 Class 5 environment with Grade A air supply, and container closure integrity is verified by dye ingress according to USP <1207>. For lyophilized presentations, mannitol is used as crystalline bulking agent, and primary drying chamber pressure is set at 50–80 mTorr with shelf temperature −20 °C; the product temperature must remain below the collapse temperature of −32 °C. Cake collapse is observed if product temperature rises above −28 °C, producing shrinkage and increased reconstitution time beyond 90 s.

Compared with chemical diastereomeric salt resolution, the biocatalytic isolate contains no detectable chiral amine resolving agent by GC-MS at a reporting limit of 10 ppm. Classical resolution often requires residual amine removal by additional acid-base partitioning; if this step is omitted, nitrogen-containing impurities can form amides during downstream tablet coating or ester prodrug synthesis. Compared with transition-metal-catalyzed asymmetric hydrogenation of atropic acid derivatives, BC-PPA-01 and BC-PPA-02 do not introduce palladium, rhodium, or ruthenium above 1 ppm; the ICH Q3D Option 2A oral permitted daily exposure for palladium is 100 µg/day, but the product remains below the reporting threshold in routine release. Dissolution testing on immediate-release tablets containing 50 mg of BC-PPA-01 shows a mean release of 85% within 30 min in pH 6.8 phosphate buffer using USP apparatus II at 50 rpm. This release profile is comparable to chemically resolved material, while the lot-to-lot enantiomeric excess range is narrower, reducing downstream chiral purity testing burden.

Both grades are stored at 15–25 °C in sealed double polyethylene bags with desiccant; re-test interval after first opening is 12 months when storage is maintained at ≤25 °C and ≤40% relative humidity. The powder is incompatible with strong oxidizing agents. Hammer milling at high speed is not recommended because localized heat above 50 °C increases amorphous fraction beyond 5% and changes compaction behavior. If particle size reduction is required, nitrogen jet milling at ≤3 bar and feed rate 5 kg/h yields D90 ≤20 µm without polymorphic form change.